首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Breast Cancer Research

Breast Cancer Research杂志,由BioMed Central出版,于1999年创刊,Bimonthly,出版语言English,ISSN:1465-542X,E-ISSN:1465-542X。

投稿咨询
Breast Cancer Research
Breast Cancer Research
Breast Cancer Research
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
6.2
CiteScore
8.1
期刊收录
SCI、SCIE

Breast Cancer Research(中文译名:《乳腺癌研究》),ISSN:1465-542X,EISSN:1465-542X,是BioMed Central出版的国际性学术期刊,创刊于1999年,以Bimonthly形式稳定发行,2026年总发文量约236篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达6.2,2025年期刊CiteScore为8.1,2025年期刊自引率约3.2%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Breast Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Italy、Sweden、Canada、GERMANY (FED REP GER)、Australia等为核心发文国家与地区;UNIVERSITY OF LONDONUNIVERSITY OF TEXAS SYSTEM、HARVARD UNIVERSITY、KAROLINSKA INSTITUTET、UNICANCER、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF MELBOURNE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 60 / 333

82.1

学科:ONCOLOGY SCIE Q1 59 / 333

82.43

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 49 / 322

84.9

学科:ONCOLOGY SCIE Q1 47 / 322

85.56


中国学者近期发文

1
AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screenin

Author:Wang, Xin-ping; Han, Ying; Yao, Min; Gao, Hong-Wen; Sun, Ping-Li

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02261-4

2
TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtype

Author:Wang, Ruyuan; Liu, Sunyan; Zhao, Yuxi; Su, Yuhang; Peng, Qiyue; Zhu, Linsha; Zheng, Yiqiu; Xin, Ying; Li, Jiasu; Du, Yaying; Li, Ke; Li, Xingrui

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02241-8

3
CD19+Ki67+B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasi

Author:Zhou, Qiyi; Zhu, Zhimin; Zhao, Yuxin; Jing, Di; Zhang, Liyuan

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02251-6

4
Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 stud

Author:Zou, La; Tang, Xianjun; Deng, Pan; Liu, Yijing; Yang, Ti; Tan, Xin; Yang, Lu; Li, Wei; Zeng, Xiaohua

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02254-3

5
FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug deliver

Author:Chen, Jinjin; Ma, Liang; Yin, Ming; Sun, Jian; Sun, Yunhao

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02247-2

6
Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cance

Author:Zhang, Nana; Zhang, Jian; Shao, Junchao; Huang, Zhenfeng; Zhang, Jinxing; Wang, Hao; Lv, Liangshuang; Shen, Zibo; Zhang, Peng; Liu, Bing; Zhang, Guoqiang; Shan, Ming

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02240-9

7
Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factor

Author:Mao, Xunyuan; Cao, Xiangyu; Qian, Long; Gao, Meng; Zhang, Naidong; Huang, Mengmeng; Fan, Peng; Qi, Ziwei; Liu, Tingkun; Zhang, Hongjie; Huang, Yuhui

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02229-4

8
O-GlcNAcylation regulates the DNA damage repair function of MND1 in breast cance

Author:Zhai, Zhen; Wu, Jinpeng; Wei, Yumeng; Song, Ping; Wang, Meng; Lin, Shuai; Ma, Xiaobin; Lu, Yurong; Yang, Pengbo; Tan, Zengqi; Guan, Feng; Li, Xiang; Kang, Huafeng

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02233-8

9
Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 tria

Author:Teng, Xinzhi; Zhang, Jiang; Lai, Qingpei; Li, Wen; Fan, Xinyu; Zhang, Xinyu; Huang, Yu-hua; Wang, Jiahuan; Liu, Chenyang; Ren, Ge; Zaidi, Habib; Lee, Elaine Yuen Phin; El Helali, Aya; Zhao, Lina; Sun, Defeng; Cai, Jing

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02219-6

10
Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cance

Author:Yang, Lei; Chen, Zhenzhou; Chen, Yajun; Yang, Jian; Liu, Shengchun; Deng, Kun; Xu, Jianping; Cui, Ming; Fu, Zhongxue

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02230-x


在线咨询

Breast Cancer Research

国际简称:BREAST CANCER RES参考译名:乳腺癌研究

年发文量:236 CiteScore:8.1 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:97.46%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Breast Cancer Research